XL092 and Cemiplimab in BRAF WT Thyroid Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

XL092 and Cemiplimab in BRAF WT Thyroid Cancer — Stella

Recruiting

Back to Anaplastic Thyroid Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

Dana Farber/Harvard Cancer Center, Boston, Massachusetts

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Key details

Phase

Early testing

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

Regeneron Pharmaceuticals, Exelixis

Enrollment target

~12 participants

Started

June 2025

Primary completion

March 2028

Age range

18 Years and older

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov